Medical Analysis

Comprehensive Medical Analysis of Factor VII, Extrinsic Coagulation Pathways, and Clinical Biomarkers

Introduction – Factor VII

Factor VII is known by several synonyms, including cothromboplastin, proconvertin, and stable factor [1, 2]. It is a vitamin K-dependent serine protease produced by the liver. Factor VII is a unique coagulation factor comprising a small proportion (1% to 3%) of a free circulating activated form (FVIIa), even in the absence of coagulation activation [3, 4]. Factor VIIa is synthesized by man and is utilized to stop bleeding by forming a blood clot in patients with hemophilia A and B [8]. In the extrinsic pathway, it initiates the process of coagulation along with tissue factor (TF/Thromboplastin/Factor VII) [3, 4]. Congenital deficiency of Factor VII is referred to as prothrombin conversion accelerator deficiency or Alexander’s disease [5, 6].

Physiological Role of Factor VII and Extrinsic Pathway Mechanisms

Tissue factor is found on the outside of blood vessels and is normally not exposed to the bloodstream [3]. Upon vessel injury, tissue factor is exposed to the blood and circulating Factor VII, which initiates the process of coagulation [3, 4]. During contact and surface injury by any means, Factor VII is converted to Factor VIIa, forming the TF-VIIa complex with tissue factor [3, 4]. This complex activates Factor X to Factor Xa [4]. Factor Xa is a serine protease which cleaves prothrombin to generate thrombin and lies at the crossroads of the extrinsic and intrinsic coagulation pathways [4, 8]. Only a small amount of Factor Xa is needed to generate many molecules of thrombin [2]. In the common pathway, the prothrombinase complex converts prothrombin (Factor II) into thrombin (Factor II A), which subsequently converts fibrinogen (Factor I) into fibrin (Factor I A) and activates Factor XIII to Factor XIII A, culminating in clot formation [1, 8].

Clinical Presentation of Factor VII Deficiency

Common symptoms of Factor VII deficiency include epistaxis, gum bleeding, easy bruising, and prolonged or excessive bleeding following surgery or physical injury [5, 6]. Rare symptoms include hemarthrosis and hematuria [5, 6]. Inherited deficiency of Factor VII (FVII) disorder is transmitted in an autosomal recessive manner [10]. Laboratory evaluations typically demonstrate a normal aPTT and bleeding time with a prolonged PT, necessitating a specific Factor VII assay for precise diagnosis [5, 6, 7].

Clinical Indications for Factor VII Testing

• Unexplained bleeding symptoms [7]

• Prolonged prothrombin time (PT) [7]

• Family history of bleeding disorders [10]

• Suspected congenital Factor VII deficiency [5, 6]

• Monitoring known bleeding disorders or acquired Factor VII deficiencies [5, 6, 9]

• Recurrent bleeding episodes like menorrhagia or bruising [5, 6]

• Assessment in patients with hemophilia inhibitors or those requiring recombinant Factor VIIa therapy [8]

Patient Instructions Prior to Testing

• Avoid anticoagulants (Warfarin) at least 2 weeks prior to testing [7].

• Avoid direct Xa, heparin, and thrombin inhibitors at least 3 days prior to testing [7].

• Do not draw blood samples from a heparinized catheter [7].

Specimen Collection and Handling Protocols

For citrated plasma collection, gather 9 parts blood to that of 3.8% Trisodium citrate solution present in the vial [7]. Separate plasma immediately, freeze plasma rapidly, and transport the specimen to the laboratory on dry ice in a suitable container [7]. As far as possible, carry out testing within four hours from the time of specimen collection [7]. If the patient’s hematocrit exceeds 65%, the volume of citrate in the collection tube must be adjusted [7]. For those patients with a hematocrit greater than 65%, use the following formula to determine the correct anticoagulant volume: Citrate = (1.85 x 10-3) x (100 – HCT) x (Blood volume), where C is the volume of citrate remaining in the tube, HCT is the patient’s hematocrit, and V is the volume of blood to be added (if a 5-mL tube is used, V = 4.5 mL) [7]. For immunohistochemistry, formalin-fixed tissue embedded in a paraffin block is used for this test [7].

Assay Methods and Detection Techniques

Assay methods for citrated plasma utilize electromagnetic mechanical clot detection [7]. For immunohistochemistry, staining for Factor VII shows positivity in megakaryocytes (x100) [7]. Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with features of both a myeloproliferative neoplasm and a myelodysplastic syndrome [7].

Antigen Staining Patterns and Internal Controls

Factor VII positivity exhibits a cytoplasmic staining pattern [7]. For the control, Factor VII-related antigen staining shows strongly positive endothelial cells lining vascular channels [7].

Normal Reference Ranges (% Activity)

Causes of Abnormally Low Factor VII Activity

Abnormally low activity of Factor VII is seen in Factor VII deficiency (a bleeding disorder that affects the ability of blood to clot) [5, 6], fat malabsorption [9], Disseminated Intravascular Coagulation (DIC) [9], liver cirrhosis [9], vitamin K deficiency [9], and taking blood thinners [7].

Activity Levels and Severity of Factor VII Deficiency

Prognostic Significance

Many women with Factor VII deficiency have heavy or prolonged menstrual bleeding (menorrhagia) [5, 6]. Severely affected individuals have an increased risk of bleeding inside the skull (intracranial hemorrhage) or in the gastrointestinal tract, which can be life-threatening [5, 6]. Inherited Factor VII deficiency is a lifelong condition [5, 6, 10]. The prognosis for acquired Factor VII deficiency depends on the underlying cause; for instance, if it is caused by liver disease, results will be alarming unless the liver disease can be treated [9].

Differentiation Between Congenital and Acquired Disorders

To differentiate between congenital and acquired disorders, control plasma is added to the patient’s plasma [7]. If corrected, it points to an acquired deficiency [7]. If activity remains less than normal and is not corrected, it indicates a congenital deficiency where inhibition factors are present [5, 6, 7].

Factor VII Immunohistochemistry (IHC) Results Interpretation

Diagnostic Utility Across Clinical Scenarios

Comprehensive Summary of Clinical Significance

For Non-Medicos

Understanding Factor VII and Blood Clotting

Factor VII is a crucial liver-made protein that partners with tissue factor to jumpstart blood clotting when injury occurs [3, 4]. Low levels lead to bleeding issues like nosebleeds or heavy periods, while genetic or acquired deficiencies can result from liver disease, vitamin K shortages, or blood thinners [5, 6, 7, 9].

Preparing for Your Blood Test

Prior to your test, stop taking blood thinners like Warfarin for two weeks and other inhibitors for three days [7]. Avoid drawing blood through a heparinized catheter to prevent inaccurate results [7].

What Your Test Results Mean

Normal activity spans broadly across ages [7]. Deficiencies are categorized from mild to very severe based on remaining percentage activity, guiding treatments like replacement therapy or vitamin K [5, 6, 7, 8, 9].

References:

1. Davie, E. W., & Ratnoff, O. D. (1964). Waterfall sequence for intrinsic blood clotting. Science, 145(3638), 1310–1312.

2. Macfarlane, R. G. (1964). An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature, 202(4931), 498–499.

3. Nemerson, Y. (1988). Tissue factor and hemostasis. Blood, 71(1), 1–8.

4. Broze, G. J. (1992). The tissue factor pathway inhibitor and the revised coagulation cascade. Seminars in Hematology, 29(3), 159–169.

5. Mariani, G., & Mazzucconi, M. G. (1983). Factor VII deficiency: an arbitrary clinical-laboratory overview. Haemostasis, 13(6), 400–407.

6. Girolami, A., Fabris, F., Dal Bo Zanon, R., Ghiotto, G., & Burul, A. (1978). Factor VII deficiency: a description of 16 cases and a critical review of the literature. Acta Haematologica, 60(2), 65–75.

7. Triplett, D. A. (2000). Coagulation assays. American Journal of Clinical Pathology, 114(Suppl 1), S98–S111.

8. Hoffman, M., & Monroe, D. M. (2001). A cell-based model of hemostasis. Thrombosis and Haemostasis, 85(6), 958–965.

9. Mammen, E. F. (1998). Coagulation abnormalities in liver disease. The Gastroenterologist, 6(1), 16–23.

10. Seligsohn, U., & Zivelin, A. (1997). The genetics of hereditary blood clotting disorders: coagulation factor VII deficiency as a model. Thrombosis and Haemostasis, 78(1), 694–698.

11. Lane, D. A., Grant, P. J., & Gray, S. (1994). Genetic risk factors for venous thrombosis. Blood Coagulation & Fibrinolysis, 5(5), 785–799.

FAQ’s:

• What is Factor VII?
  A liver-produced, vitamin K-dependent serine protease initiating the extrinsic coagulation pathway.

• What does Factor VII do?
  It combines with tissue factor during vessel injury to jumpstart blood clotting.

• What are deficiency symptoms?
  Symptoms include nosebleeds, gum bleeding, easy bruising, and prolonged bleeding after surgery.

• How is deficiency inherited?
  Inherited Factor VII deficiency is a lifelong disorder transmitted in an autosomal recessive manner.

• Which tests are required?
  A prolonged prothrombin time (PT) necessitates a specific Factor VII assay for diagnosis.

• How to prepare for testing?
  Avoid Warfarin for two weeks, other blood thinners for three days, and avoid catheter draws.

• How should plasma be collected?
  Mix nine parts blood with one part trisodium citrate, separate plasma, freeze, and transport rapidly.

• What causes low activity?
  Low activity stems from deficiency, liver cirrhosis, vitamin K shortages, fat malabsorption, or thinners.

• How is severity classified?
  Severity is categorized into mild, moderate, severe, and very severe based on activity percentages.

What are high levels linked to?
Elevated levels are linked with thrombotic risk, cardiovascular events, and genetic F7 polymorphisms.

Related Tests

• Prothrombin Time (PT / INR) Test
• Activated Partial Thromboplastin Time (aPTT) Test